Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MK-8189 by Merck for Schizophrenia: Likelihood of Approval
MK-8189 is under clinical development by Merck and currently in Phase II for Schizophrenia. According to GlobalData, Phase II drugs...
Human papillomavirus (virus like particle, 9-valent) vaccine by Merck for Human Papillomavirus Infections: Likelihood of Approval
Human papillomavirus (virus like particle, 9-valent) vaccine is under clinical development by Merck and currently in Phase II for Human...
Vicriviroc by Merck for Metastatic Colorectal Cancer: Likelihood of Approval
Vicriviroc is under clinical development by Merck and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Ulevostinag by Merck for Cutaneous T-Cell Lymphoma: Likelihood of Approval
Ulevostinag is under clinical development by Merck and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase...
Pembrolizumab by Merck for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Avelumab by Merck for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Avelumab by Merck for Glioblastoma Multiforme (GBM): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Pembrolizumab by Merck for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)....
Avelumab by Merck for Malignant Mesothelioma: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II...
Nedisertib by Merck for Solid Tumor: Likelihood of Approval
Nedisertib is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Nedisertib by Merck for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Nedisertib is under clinical development by Merck and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData,...
PRA-052 by Merck for Ulcerative Colitis: Likelihood of Approval
PRA-052 is under clinical development by Merck and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I...
MK-3475A by Merck for Metastatic Melanoma: Likelihood of Approval
MK-3475A is under clinical development by Merck and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
MK-3475A by Merck for Metastatic Renal Cell Carcinoma: Likelihood of Approval
MK-3475A is under clinical development by Merck and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...
MK-8527 by Merck for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
MK-8527 is under clinical development by Merck and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Enpatoran by Merck for Systemic Lupus Erythematosus: Likelihood of Approval
Enpatoran is under clinical development by Merck and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Merck's Quavonlimab?
Quavonlimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Merck's Vibostolimab?
Vibostolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Merck's Nemtabrutinib?
Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Chronic Lymphocytic Leukemia (CLL). According...
Risk adjusted net present value: What is the current valuation of Merck's Favezelimab?
Favezelimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...